US › Healthcare

Phio Pharmaceuticals Corp (PHIO)

US · Healthcare · Biotechnology

$1.06+2.91%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-4.0M
Profit YoY
-126.3%
EPS
$-0.34
EPS estimate
$-0.23

EPS came in at -0.34 against a street estimate of -0.23 — a miss of 47.8%.

Key statistics

Market cap
$11.4M
Forward P/E
0.3
P/B
0.71
Book value
$1.42
EPS (TTM)
$-1.34
52-week high
$2.57
52-week low
$0.81
50-day MA
$1.05
200-day MA
$1.23
Beta
0.81

Analyst view

Analysts rate Phio Pharmaceuticals Corp a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $14.00.

Shareholding

Insiders
1.93%
Institutions
10.81%

Largest institutional holders

FundStake
Geode Capital Management, LLC1.27%
Jane Street Group LLC1.03%
Vanguard Group Inc0.75%
Vanguard Capital Management, LLC0.69%
Cetera Investment Advisers0.39%
Vanguard Fiduciary Trust Co0.33%
HRT FINANCIAL LLC0.30%
Two Sigma Investments LLC0.28%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Phio Pharmaceuticals Corp — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.